Primary lymphoma of the nervous system

Cancer Journal

Volumn 12, Issue 1, 2006, Pages 1-13

  Baehring, Joachim M ^a   Hochberg, Fred H ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Intravascular lymphoma; Methotrexate; Neurolymphomatosis; Ocular lymphoma; Posttransplant lymphoproliferative disorder; Primary CNS lymphoma

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TUMOR MARKER; VINCRISTINE; VINDESINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; BRAIN; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INFILTRATION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CRANIAL NERVE; DOSE RESPONSE; DRUG MEGADOSE; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; EYE; EYE CANCER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LYMPHOMA; MEDLINE; MENINX; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NERVOUS SYSTEM; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PERIPHERAL NERVE; PRIMARY NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REVIEW; SPINAL NERVE; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; EYE NEOPLASMS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; METHOTREXATE; NERVOUS SYSTEM NEOPLASMS; ORGAN TRANSPLANTATION; RADIOTHERAPY;

EID: 33645866456     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200601000-00001     Document Type: Review

References (108)

1. Central Brain Tumor Registry of the United States. 1995-1999 data. http://www.cbtrus.org. 2002.
2. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988;68:835-853.
3. Lutz JM, Coleman MP. Trends in primary cerebral lymphoma. Br J Cancer 1994;70:716-718.
4. Olson JE, Janney CA, Rao RD et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002;95:1504-1510.
5. Hollender A, Kvaloy S, Lote K et al. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 2000;36:1762-1768.
6. Keldsen N, Michalski W, Bentzen SM et al. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma - a multivariate analysis. Acta Oncol 1996;35:703-708.
7. Young RC, Howser DM, Anderson T et al. Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. Am J Med 1979;66:435-443.
8. Cassoux N, Merle-Beral H, Leblond V et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 2000;8:243-250.
9. Cingolani A, Gastaldi R, Fassone L et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol 2000;18:3325-3330.
10. Ammassari A, Cingolani A, Pezzotti P et al. AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 2000;55:1194-1200.
11. Chow KU, Mitrou PS, Geduldig K et al. Changing incidence and survival in patients with AIDS-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2001;41:105-116.
12. Newell ME, Hoy JF, Cooper SG et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer 2004;100:2627-2636.
13. Castellano-Sanchez AA, Li S, Qian J et al. Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 2004;121:246-253.
14. Leblond V, Dhedin N, Mamzer Bruneel MF et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001;19:772-778.
15. Phan TG, O'Neill BP, Kurtin PJ. Posttransplant primary CNS lymphoma. Neuro-oncol 2000;2:229-238.
16. Hayabuchi N, Shibamoto Y, Onizuka Y. Primary central nervous system lymphoma in Japan: a nationwide survey. Int J Radiat Oncol Biol Phys 1999;44:265-272.
17. Shenkier TN, Blay JY, O'Neill BP et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005;23:2233-2239.
18. Al Yamany M, Lozano A, Nag S et al. Spontaneous remission of primary central nervous system lymphoma: report of 3 cases and discussion of pathophysiology. J Neurooncol 1999;42:151-159.
19. Alderson L, Fetell MR, Sisti M et al. Sentinel lesions of primary CNS lymphoma. J Neurol Neurosurg Psychiatry 1996;60:102-105.
20. Brecher K, Hochberg FH, Louis DN et al. Case report of unusual leukoencephalopathy preceding primary CNS lymphoma. J Neurol Neurosurg Psychiatry 1998;65:917-920.
21. Pirotte B, Levivier M, Goldman S et al. Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature. J Neurooncol 1997;32:63-69.
22. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 1999;43:237-239.
23. Bashir R, Coakham H, Hochberg F. Expression of LFA-1/ICAM-1 in CNS lymphomas: possible mechanism for lymphoma homing into the brain. J Neurooncol 1992;12:103-110.
24. Larocca LM, Capello D, Rinelli A et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 1998;92:1011-1019.
25. Weber, T, Weber RG, Kaulich K et al. Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type. Brain Pathol 2000;10:73-84.
26. Nakamura M, Kishi M, Sakaki T et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 2003;63:737-741.
27. Albrecht S, Bruner JM, Segall GK. Immunoglobulin heavy chain rearrangements in primary brain lymphomas. A study using PCR to amplify CDR-III. J Pathol 1993;169:297-302.
28. Julien S, Radosavljevic M, Labouret N et al. AIDS primary central nervous system lymphoma: molecular analysis of the expressed VH genes and possible implications for lymphomagenesis. J Immunol 1999;162:1551-1558.
29. Montesinos-Rongen M, Kuppers R, Schluter D et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999;155:2077-2086.
30. Thompsett AR, Ellison DW, Stevenson FK et al. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 1999;94:1738-1746.
31. Braaten KM, Betensky RA, de Leval L et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003;9:1063-1069.
32. Shen DF, Zhuang Z, LeHoang P et al. Utility of microdissection and polymerase chain reaction for the detection of immunoglobulin gene rearrangement and translocation in primary intraocular lymphoma. Ophthalmology 1998;105:1664-1669.
33. Montesinos-Rongen M, Van Roost D, Schaller C et al. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004;103:1869-1875.
34. Pasqualucci L, Neumeister P, Goossens T et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-346.
35. Zhang, SJ, Endo S, Ichikawa T et al. Frequent deletion and 5′ CpG island methylation of the p16 gene in primary malignant lymphoma of the brain. Cancer Res 1998;58:1231-1237.
36. Jordanova ES, Riemersma SA, Philippo K et al. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 2002;35:38-48.
37. Bashir R, Luka J, Cheloha K et al. Expression of Epstein-Barr virus proteins in primary CNS lymphoma in AIDS patients. Neurology 1993;43:2358-2362.
38. Hochberg FH, Miller G, Schooley RT et al. Central-nervous-system lymphoma related to Epstein-Barr virus. N Engl J Med 1983;309:745-748.
39. Cleary ML, Epstein MA, Finerty S et al. Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science 1985;228:722-724.
40. Seiden MV, Sklar J. Molecular genetic analysis of post-transplant lymphoproliferative disorders. Hematol Oncol Clin North Am 1993;7:447-465.
41. Akpek EK, Ahmed I, Hochberg FH et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 1999;106:1805-1810.
42. Freilich RJ, DeAngelis LM. Primary central nervous system lymphoma. Neurol Clin 1995;13:901-914.
43. Maher EA, Fine HA. Primary CNS lymphoma. Semin Oncol 1999;26:346-356.
44. Baehring JM, Damek D, Martin EC et al. Neurolymphomatosis. Neuro-oncol 2003;5:104-115.
45. Baehring JM, Longtine J, Hochberg FH. A new approach to the diagnosis and treatment of intravascular lymphoma. J Neurooncol 2003;61:237-248.
46. DiGiuseppe JA, Nelson WG, Seifter EJ et al. Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J Clin Oncol 1994;12:2573-2579.
47. Glass J, Hochberg FH, Miller DC. Intravascular lymphomatosis. A systemic disease with neurologic manifestations. Cancer 1993;71:3156-3164.
48. Buggage RR, Chan CC, Nussenblatt RB. Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 2001;13:137-142.
49. Buhring U, Herrlinger U, Krings T et al. MRI features of primary central nervous system lymphomas at presentation. Neurology 2001;57:393-396.
50. Johnson BA, Fram EK, Johnson PC et al. The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol 1997;18:563-572.
51. Baehring JM, Henchcliffe C, Ledezma CJ et al. Intravascular lymphoma: magnetic resonance imaging correlates of disease dynamics within the central nervous system. J Neurol Neurosurg Psychiatry 2005;76:540-544.
52. Harting I, Hartmann M, Jost G et al. Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett 2003;342:163-166.
53. Raizer JJ, Koutcher JA, Abrey LE et al. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol 2005;71:173-180.
54. Hartmann M, Heiland S, Harting I et al. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 2003;338:119-122.
55. Gleissner B, Siehl J, Korfel A et al. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002;58:390-396.
56. Cingolani A, De Luca A, Larocca LM et al. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst 1998;90:364-369.
57. Ivers LC, Kim AY, Sax PE. Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis 2004;38:1629-1632.
58. Schultz C, Scott C, Sherman W et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996;14:556-564.
59. Cher L, Glass J, Harsh GR et al. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996;46:1757-1759.
60. Gabbai AA, Hochberg FH, Linggood RM et al. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. J Neurosurg 1989;70:190-194.
61. Glass J, Gruber ML, Cher L et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188-195.
62. Glass J, Shustik C, Hochberg FH et al. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neurooncol 1996;30:257-265.
63. Guha-Thakurta N, Damek D, Pollack C et al. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999;43:259-268.
64. Hochberg FH, Loeffler JS, Prados M. The therapy of primary brain lymphoma. J Neurooncol 1991;10:191-201.
65. Batchelor T, Carson K, O'Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044-1049.
66. Freilich RJ, Delattre JY, Monjour A et al. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996;46:435-439.
67. Herrlinger U, Kuker W, Uhl M et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 2005;57:843-847.
68. Herrlinger U, Schabet M, Brugger W et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann. Neurol 2002;51:247-252.
69. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:31443150.
70. Boiardi A, Silvani A, Pozzi A et al. Chemotherapy is effective as early treatment for primary central nervous system lymphoma. J Neurol 1999;246:31-37.
71. Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin. Oncol 2003;21:2726-2731.
72. Pels H, Schmidt-Wolf IG, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489-4495.
73. DeAngelis LM, Seiferheld W, Schold SC et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-4648.
74. O'Brien P, Roos D, Pratt G et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000;18:519-526.
75. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003;21:4483-4488.
76. Doolittle ND, Miner ME, Hall WA et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000;88:637-647.
77. Glantz MJ, Cole BF, Recht L et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998;16:1561-1567.
78. Khan RB, Shi W, Thaler HT et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002;58:175-178.
79. Plotkin SR, Betensky RA, Hochberg FH et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin. Cancer Res 2004;10:5643-5646.
80. Fischer L, Thiel E, Klasen HA et al. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 2004;62:1885-1887.
81. Herrlinger U, Brugger W, Bamberg M et al. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 2000;54:1707-1708.
82. Reni M, Ferreri AJ, Villa E. Second-line treatment for primary central nervous system lymphoma. Br J Cancer 1999;79:530-534.
83. Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM et al. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003;70:219-224.
84. Enting RH, Demopoulos A, DeAngelis LM et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901-903.
85. Pels H, Schulz H, Schlegel U et al. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003;26:351-354.
86. Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466-468.
87. Lerro KA, Lacy J. Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response. J Neurooncol 2002;59:165-168.
88. Boiardi A, Silvani A, Pozzi A et al. Radiotherapy at tumor recurrence in primary CNS lymphoma. Neurology 1998;50:1934-1935.
89. Nguyen PL, Chakravarti A, Finkelstein DM et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005;23:1507-1513.
90. Cheng T, Forsyth P, Chaudhry A et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003;31:679-685.
91. Soussain C, Suzan F, Hoang-Xuan K et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001;19:742-749.
92. Abrey LE, Moskowitz CH, Mason WP et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151-4156.
93. Macdonald DR, Cascino TL, Schold SC Jr et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
94. Fliessbach K, Urbach H, Helmstaedter C et al. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 2003;60:563-568.
95. Lai R, Abrey LE, Rosenblum MK et al. Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 2004;62:451-456.
96. McAllister LD, Doolittle ND, Guastadisegni PE et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000;46:51-60.
97. Schlegel U, Pels H, Oehring R et al. Neurologic sequelae of treatment of primary CNS lymphomas. J Neurooncol 1999;43:277-286.
98. Correa DD, DeAngelis LM, Shi W et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004;62:548-555.
99. Harder H, Holtel H, Bromberg JE et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004;62:544-547.
100. Forsyth PA, Yahalom J, DeAngelis LM. Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 1994;44:1473-1479.
101. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003;17:1787-1793.
102. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995;59:240-244.
103. Porcu P, Eisenbeis CF, Pelletier RP et al. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood 2002;100:2341-2348.
104. Roychowdhury S, Peng R, Baiocchi RA et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 2003;63:965-971.
105. Batchelor TT, Kolak G, Ciordia R et al. High-dose methotrexate for intraocular lymphoma. Clin. Cancer Res 2003;9:711-715.
106. Smith JR, Rosenbaum JT, Wilson DJ et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-1716.
107. Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17.
108. O'Neill P, O'Fallon JR, Earle JD et al. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 1995;33:663-673.